


Colloquium

"Challenges in drug and vaccine research: Targeting SARS-CoV-2"

November 25th, 2020

Web-based Meeting via Zoom:
link on request (grk2504-info@fau.de)



GRK 2504

Novel antiviral approaches

PART I

Chaired by Annika Schnell, Stephan Kohrt

9:30 Prof. Dr. Klaus Überla

Institute of Clinical and Molecular Virology,
Universitätsklinikum Erlangen

Welcome Note

9:35 Dr. Jens Vollmar

GlaxoSmithKline GmbH & Co. KG, Munich
Vaccine development under high pressure -
a perspective of a research-based vaccine
manufacturer

10:35 Prof. Dr. Robin Shattock

Mucosal Infection and Immunity, Department of
Medicine, Imperial College, London

Development of a COVID-19 self-amplifying
RNA vaccine

11:35 Break

11:50 PD Dr. Dr. Anita Kremer

Medicine 5, Universitätsklinikum Erlangen
SARS-CoV-2 specific T-cell responses

12:10 Prof. Dr. Gerd Sutter

Institute for Infectious Diseases and Zoonoses,
Ludwig-Maximilians-Universität Munich

Vaccines against emerging infections:
Development of MVA-SARS-2-S - The DZIF
COVID-19 vaccine candidate

13:10 Lunch break

Organisation: Prof. Dr. Klaus Überla, Dr. Andrea Thoma-Kreß, Karin Ertl and by GRK2504 students Markus Wild, Alexandra Birzer,
Stephan Kohrt, Annika Schnell

Contact: GRK2504-info@fau.de, Tel: 09131 85-25975

PART II

Chaired by Alexandra Birzer, Markus Wild

14:00 Dr. Nadine Salisch

Viral Vaccines, Janssen Vaccines & Prevention B.V.
N.N.

15:00 Prof. Dr. Matthias Tenbusch

Institute of Clinical and Molecular Virology,
Universitätsklinikum Erlangen
Mucosal vaccination against SARS-CoV-2

15:25 Prof. Dr. Manfred Marschall

Institute of Clinical and Molecular Virology,
Universitätsklinikum Erlangen
Strategies of developing direct-acting and host-
directed antivirals against SARS coronavirus type 2

15:55 Break

16:10 Prof. Dr. Ralf Wagner

Institute of Medical Microbiology and Hygiene,
University of Regensburg

Crucial role of the S protein receptor binding domain
in developing SARS-CoV-2 diagnostics and vaccines

17:10 Prof. Dr. Hans-Martin Jäck

Division of Immunology, Medicine 3,
Universitätsklinikum Erlangen
COVID-19 and Plasma Cells

18:10 Dr. Andrea Thoma-Kreß

Institute of Clinical and Molecular Virology,
Universitätsklinikum Erlangen

Concluding Remarks

